Log In
Print
BCIQ
Print
Print this Print this
 

Kerydin, tavaborole (AN2690)

  Manage Alerts
Collapse Summary General Information
Company Anacor Pharmaceuticals Inc.
DescriptionTopical oxaborole antifungal agent
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationOnychomycosis
Indication DetailsTreat onychomycosis
Regulatory Designation

U.S. - Special Protocol Assessment (Treat onychomycosis);
U.S. - Undisclosed Review (Treat onychomycosis)

Partner

Novartis AG


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today